Lack of efficacy (ectoparasite) - NOS

Verify with FDA CVM →

VeDDRA Code: 2492

2,119 adverse event reports referencing this reaction

2,119
Total Reports
5
Deaths
20.0%
Death Rate

Species Most Affected

Dog 1,835
Cattle 186
Cat 86
Unknown 2
Horse 2
Other 2
Rabbit 1
Hamster 1
Alpaca 1
Sheep 1

Breeds Most Affected

Dog (unknown) 300
Crossbred Canine/dog 211
Retriever - Labrador 125
Chihuahua 90
Shih Tzu 80
Terrier - Yorkshire 73
Shepherd Dog - German 56
Retriever - Golden 56
Pit Bull 49
Cattle (other) 47

Associated Drugs

Fluralaner Chew Tablets 1,042
Afoxolaner 292
Afoxolaner 28.3 Mg Chewable Tablets 86
Fluralaner 13.64% 12-Week Chew 61
Afoxolaner 11.3 Mg Chewable Tablets 57
Lotilaner 56
Imidacloprid 50
Afoxolaner 68 Mg Chewable Tablets 48
Eprinomectin 47
Selamectin 42
Afoxolaner 136 Mg Chewable Tablets 39
Portech App Gun 65 Ml Ivomec/Eprinex 38
Pyrantel Pamoate;Sarolaner 35
Ivermectin 33
Moxidectin 31
Fluralaner Spot-On Solution 30
Eprinomectin 5 Mg/Ml Pour-On Solution 29
Nitenpyram 23
Doramectin 21
Ivermectin 0.5% Pour-On Topical Solution 21

Data Summary

Metric Value
Total reports referencing reaction 2,119
Reports with fatal outcome 5
Case-fatality rate (reported events) 20.0%
Species observed 10
Breeds observed 20
Drugs associated with reaction 20

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER); reaction term coded under VeDDRA 2492.

Lack of efficacy (ectoparasite) - NOS Reaction Insights

The FDA Center for Veterinary Medicine database currently lists 2,119 adverse event reports that reference Lack of efficacy (ectoparasite) - NOS as a reaction term, including 5 reports with a death outcome — a 20.0% case-fatality figure calculated across only those events where this reaction was coded. The reaction is indexed in the openFDA system under VeDDRA code 2492, the standardized veterinary dictionary used to normalize clinical signs across submitters. Because reports are voluntary and often describe multiple concurrent signs per animal, the volume here reflects reporting intensity rather than true incidence in the broader pet population.

Lack of efficacy (ectoparasite) - NOS appears most frequently in reports for Dog (1,835 reports), Cattle (186 reports), Cat (86 reports) — with Dog dominating at 1,835 entries. Within those species, the breeds most often named alongside this reaction are Dog (unknown) (300), Crossbred Canine/dog (211), Retriever - Labrador (125). These distributions are influenced both by underlying breed popularity and by how veterinarians and owners code a given clinical sign, so they should be interpreted as a reporting fingerprint rather than a pure susceptibility ranking.

The drugs most commonly co-reported with Lack of efficacy (ectoparasite) - NOS are Fluralaner Chew Tablets (1,042 reports), Afoxolaner (292 reports), Afoxolaner 28.3 Mg Chewable Tablets (86 reports), Fluralaner 13.64% 12-Week Chew (61 reports), with Fluralaner Chew Tablets appearing alongside this reaction in 1,042 submissions. Co-reporting does not establish that any specific product caused the reaction — FDA CVM data captures temporal association only. The value of these aggregates is in flagging which therapeutic classes appear repeatedly alongside a given clinical sign, so owners and veterinarians can ask targeted questions about medications currently in use.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial